Compelling evidence indicates that two autosomal recessive Parkinson's disease genes, PINK1 (PARK6) and Parkin (PARK2), cooperate to mediate the autophagic clearance of damaged mitochondria (mitophagy). Mutations in the F-box domain-containing protein Fbxo7 (encoded by PARK15) also cause early-onset autosomal recessive Parkinson's disease, by an unknown mechanism. Here we show that Fbxo7 participates in mitochondrial maintenance through direct interaction with PINK1 and Parkin and acts in Parkin-mediated mitophagy. Cells with reduced Fbxo7 expression showed deficiencies in translocation of Parkin to mitochondria, ubiquitination of mitofusin 1 and mitophagy. In Drosophila, ectopic overexpression of Fbxo7 rescued loss of Parkin, supporting a functional relationship between the two proteins. Parkinson's disease-causing mutations in Fbxo7 interfered with this process, emphasizing the importance of mitochondrial dysfunction in Parkinson's disease pathogenesis.
Parkinson's disease is the second most common neurodegenerative disorder. Mutations in several genes have been linked to familial forms of Parkinson's disease, and studying the function of their proteins has been valuable in highlighting pathways that may be important in the pathogenesis of familial and sporadic forms of the disease. Two of these, PINK1 (PTEN-induced putative kinase 1), a mitochondrial kinase, and Parkin, an E3 ubiquitin ligase, act in a common pathway to control turnover of mitochondria. Upon treatment of cells with a mitochondrial uncoupler, carbonyl cyanide 3-chlorophenylhydrazone (CCCP), Parkin is recruited to depolarized mitochondria, which enables their selective autophagic clearance (mitophagy) 1 . This recruitment requires the kinase activity of PINK1 (refs. 2-4) , which is cleaved from the mitochondria under basal conditions but whose full-length form accumulates on depolarized mitochondria under CCCP treatment [5] [6] [7] . Parkin recruitment to mitochondria leads to ubiquitination of several targets, including mitochondrial fusion proteins, mitofusins (Mfns) [8] [9] [10] [11] [12] [13] , which promotes mitochondrial fragmentation before engulfment by the autophagosome 14 .
Mutations in the gene encoding F-box only protein 7 (Fbxo7) have been identified in families with a severe form of autosomal recessive early-onset Parkinson's disease similar to that caused by mutations in PINK1 or Parkin [15] [16] [17] . F-box domain-containing proteins target substrates to SCF-type (Skp1-Cul1-F-box) E3 ubiquitin ligase complexes, usually by recruiting the substrate through a protein interaction domain and assembling a functional E3 ligase by associating with the adaptor protein Skp1 through an F-box domain 18 . Fbxo7 has a C-terminal proline-rich substrate recruiting domain, as well as an N-terminal ubiquitin-like (Ubl) domain that is present in the major isoform of Fbxo7 but is spliced out in a second isoform (Fig. 1a) . Fbxo7 has both SCF-dependent and SCF-independent activities [19] [20] [21] [22] ; however, little is understood of its function in Parkinson's disease pathogenesis 23 . Here we demonstrate that Fbxo7 acts in a common pathway with Parkin and PINK1 to induce mitophagy in response to mitochondrial depolarization and that disease-associated mutations in Fbxo7 interfere with this pathway. We also show that Fbxo7 expression rescues the phenotype of Drosophila parkin mutants, confirming that the genes function in a common mechanism in vivo.
RESULTS

Fbxo7 interacts directly with Parkin
Given the clinical overlap between patients with Fbxo7 and Parkin mutations, we investigated whether these two proteins might be functionally related. First, we tested whether they physically interact. In whole-cell lysates extracted from U2OS human osteosarcoma cells expressing Fbxo7 tagged with a hemagglutinin (HA) epitope and Parkin tagged with a Flag epitope or in HEK293 human embryonic kidney cells expressing Flag-Parkin, we detected both exogenously expressed and endogenous Fbxo7 in complex with Parkin after immunoprecipitation (Fig. 1b,c) . The reverse experiment, immunoprecipitating overexpressed untagged Fbxo7 and immunoblotting for Flag-Parkin, confirmed their interaction (Supplementary Fig. 1a) .
To identify the interacting region, we tested T7 phage epitope-tagged Fbxo7 mutants lacking specific domains in coimmunoprecipitation assays. The N-terminal 88 amino acids of Fbxo7, which comprise 1 2 5 8 VOLUME 16 | NUMBER 9 | SEPTEMBER 2013 nature neurOSCIenCe a r t I C l e S the Ubl domain, appeared essential for an interaction (Fig. 1d) , and this was supported by the finding that Flag-Parkin interacted with isoform 1 of Fbxo7 but not with isoform 2, a naturally occurring splice variant of Fbxo7 that lacks the Ubl domain (Supplementary Fig. 1b) . Conversely, the removal of the C-terminal proline rich region of Fbxo7 did not affect the interaction with Parkin (Fig. 1e) . Cdk6  F box  Proline rich  dimerization domain   T22M  R378G  R498X   129   1   169 182  335  325  378  423  522   Isoform 1   Isoform 2 a r t I C l e S
We also performed in vitro coprecipitation assays using a glutathione S-transferase (GST)-Fbxo7(1-88) construct, which was found to be sufficient for binding, confirming that the Ubl domain of Fbxo7 directly mediates Parkin interaction (Fig. 1f) . The Parkinson's disease-associated mutation T22M lies within this domain (Fig. 1a) , and this mutation significantly reduced Fbxo7 binding to Parkin by 88% ± 3.5% (P = 0.000525; Fig. 1g and Supplementary Fig. 1d ). Both the R378G and R498X mutations caused no significant change in Parkin binding (P = 0.531 and 0.265, respectively; Supplementary  Fig. 1c,d ). Immunoprecipitating Flag-Parkin from cytosolic and mitochondrial fractions revealed that, although both proteins localize predominantly to the cytosol, the interaction occurred to a greater extent in the mitochondrial fraction (Fig. 1h) .
Fbxo7 participates in Parkin recruitment to mitochondria
As Parkin has been shown to translocate to mitochondria upon treatment with the mitochondrial uncoupler CCCP 1-4 , we investigated whether Fbxo7 also relocates to depolarized mitochondria. Over a timecourse of CCCP treatment, endogenous Fbxo7 decreased steadily in the cytosolic fraction and increased concurrently in the mitochondrial fractions of HEK293T cells (Fig. 2a) and SH-SY5Y cells (Supplementary Fig. 2a ). Immunoprecipitating Flag-Parkin complexes from the mitochondrial fraction of SH-SY5Y cells revealed an increase in Fbxo7 protein in complex with Flag-Parkin after CCCP treatment, consistent with an increase in the association of both proteins with the mitochondria following depolarization (Fig. 2b) . We next examined whether Fbxo7 regulates Parkin translocation in SH-SY5Y human neuroblastoma cells cotransfected with FlagParkin and either nontargeting, scrambled (scr) short interfering RNA (siRNA) or Fbxo7 siRNA, which substantially attenuates Fbxo7 expression ( Supplementary Fig. 2b ). At 1 and 3 h CCCP treatment, silencing Fbxo7 significantly reduced the percentage of cells in which Parkin localized to the mitochondria compared to scrambled (scr) control ( Fig. 2c and Supplementary Fig. 2c,d) , as scored by eye by an unbiased observer (see Online Methods). These data were independently confirmed by analyzing the images using Pearson's correlation coefficient (R r ) (Supplementary Fig. 2e ). The reduction in Parkin translocation upon Fbxo7 silencing was rescued by overexpression of wild-type (WT) or R378G mutant Fbxo7 but not by T22M or R498X mutant Fbxo7 (Fig. 2d) , suggesting that, in addition to binding Parkin through its N-terminal Ubl domain, Fbxo7 requires its C-terminal proline-rich region to recruit Parkin to the mitochondria.
Although Parkin is known to localize to depolarized mitochondria, it is not predicted to contain a mitochondrial targeting sequence (MTS), raising the possibility that this translocation could depend on its interaction with a mitochondrially targeted protein. In silico analysis of the primary sequence of the Fbxo7 protein suggested that it may possess such an MTS at the N terminus of isoform 1, and this prediction depended on two critical residues (Arg2 and Arg6). To investigate the relevance of this putative MTS, we produced both a T7-tagged and an untagged Fbxo7 construct in which both residues d e f
Control park 25 , da-GAL4/+ park 25 npg a r t I C l e S were mutated (hereafter designated mt-MTS) and found that, whereas a portion of WT T7-Fbxo7 was found to localize to the mitochondrial fraction of SH-SY5Y cells, mt-MTS T7-Fbxo7 did not (Fig. 2e) . Furthermore, CCCP-induced mitochondrial translocation of FlagParkin was not rescued by expression of mt-MTS Fbxo7 after silencing of endogenous Fbxo7 (Fig. 2d) , indicating that this MTS is necessary for Fbxo7's effect on Parkin relocation. None of the three Parkinson's disease-associated mutations affected the mitochondrial localization of Fbxo7 (Supplementary Fig. 2f ). Overall, these data indicate that Fbxo7 facilitates Parkin translocation to the mitochondria in response to depolarization.
Overexpression of Fbxo7 rescues parkin mutant flies
To assess a functional relationship between Fbxo7 and Parkin in vivo, we used a well-established Drosophila model, which has proven useful in uncovering the neurodegenerative and mitochondrial phenotypes in PINK1 and parkin mutants and genetic dissection of this pathway [24] [25] [26] [27] . Drosophila parkin mutants recapitulate several features of the disease phenotype, including characteristic locomotor deficits in flight and climbing ability, as well as dopaminergic neurodegeneration. The profound mitochondrial disruption evident in these mutants also leads to flight muscle degeneration and male sterility. Initial studies of transgenic lines bearing human Fbxo7 showed that ectopic expression of Fbxo7 by the strong ubiquitous daughterless (da)-GAL4 driver caused no apparent phenotypes in a WT background ( Supplementary   Fig. 3a-d) . Notably, expression of Fbxo7 significantly rescued the parkin phenotypes, including locomotor defects, dopaminergic neuron loss, muscle degeneration, and mitochondrial disruption ( Fig. 3a-f) . In contrast, the expression neither of the pathogenic mutants T22M, R378G and R498X nor of mutants lacking a functional MTS (mt-MTS or isoform 2) provided any rescue of flight or climbing ability (Fig. 3g,h ). These results show that human Fbxo7 isoform 1 can functionally substitute for loss of Parkin in vivo and that this rescue is abolished by pathogenic mutations, suggesting they share a common role in mitochondrial biology. We next sought to determine whether the Drosophila genome encodes an Fbxo7 homolog that may be required for Parkin function. Previous studies have suggested Drosophila nutcracker (ntc) is an Fbxo7 ortholog with some conserved functions 28, 29 . Although the F-box domain of ntc shares 59% identity and 65% similarity with Fbxo7, their overall sequence homology is low (28% identity, 45% similarity). In addition, ntc entirely lacks the proline-rich region of Fbxo7, with which some substrates interact. If ntc functions with Parkin in Drosophila, similar loss-of-function phenotypes would be expected. But although ntc mutant males are sterile 28 they exhibit no overt disruption of the musculature or mitochondria, no loss of flight ability and no dopaminergic neurodegeneration (data not shown), and hence they do not phenocopy parkin mutants. We also found that expression of Fbxo7 was unable to rescue male sterility in these mutants (data not shown), indicating that ntc is not likely a functional homolog of Fbxo7. (Fig. 4a) , and this was also true for the reciprocal immunoprecipitation (Supplementary Fig. 4a ). This interaction was unaffected by Fbxo7 pathogenic mutations (Supplementary Fig. 4b) . Immunoprecipitations using N-or C-terminal deletion mutants of Fbxo7 showed that this interaction also mapped to the N terminus of Fbxo7 (Fig. 4b,c) . However, unlike Parkin, PINK1 retained partial binding to a mutant Fbxo7 lacking the Ubl domain (amino acids 89-522); a further truncation to amino acid 129 ablated Fbxo7 interaction with PINK1 (Fig. 4b ). An in vitro binding assay using GST-Fbxo7(1-398) or GST-Fbxo7(129-398) with in vitro-translated epitope-tagged PINK1-Myc verified that the PINK1 interaction required the first 129 amino acids and was direct (Fig. 4d) . In support of these data, we found that PINK1 retained partial binding to Fbxo7 isoform 2, which contains amino acids 92-522 of isoform 1 (Supplementary Fig. 4c ). These data suggest that PINK1 binding is mediated by sequences in amino acids 92-129 of Fbxo7 and raise the possibility that the interactions of Fbxo7, Parkin and PINK1 may be mutually exclusive or form ternary complexes. Fbxo7 interacted with both full-length PINK1 and an N-terminal truncation (∆N-PINK1) in vitro (Fig. 4e) , indicating that the first 103 amino acids of PINK1 are dispensable for the interaction. In vitro coprecipitations of GSTFbxo7 with either full-length or ∆N-PINK1, Parkin or a combination of the two revealed that neither Parkin nor PINK1 had any significant effect on the interaction of Fbxo7 with the other protein (Fig. 4e) .
Performing the reciprocal coprecipitation with GST-Parkin or GST-∆N-PINK1 confirmed these findings (Fig. 4f) . These data suggest that Fbxo7, Parkin and PINK1 interact in a noncompetitive, nonsynergistic manner. Because we found Fbxo7 and PINK1 to interact, we sought to determine whether Fbxo7 was also required for PINK1 stabilization at the mitochondria after CCCP treatment. Consistent with previous reports 3, 4 , PINK1-HA accumulated on mitochondria following CCCP treatment. However, cells cotransfected with PINK1-HA and Fbxo7 siRNA showed no significant difference from those expressing PINK1-HA and scr siRNA in PINK1 accumulation ( Fig. 5a and Supplementary Fig. 5a,b) , indicating that Fbxo7 is not required for PINK1 stabilization. This was confirmed by immunoblot of both endogenous and overexpressed PINK1 (Supplementary Fig. 5c,d) . To determine whether Fbxo7 instead functions downstream of PINK1 in the pathway, we assessed CCCP-induced relocation of endogenous Fbxo7 to the mitochondria by immunoblotting in cells transfected with scrambled or PINK1 siRNA, or in cells overexpressing PINK1-HA. Fbxo7 relocation was substantially reduced in cells transfected with PINK1 siRNA (Fig. 5b) and increased in cells overexpressing PINK1-HA (Supplementary Fig. 5e ), indicating that PINK1 is required for its recruitment to the mitochondria.
To further investigate the functional relationship between Fbxo7 and PINK1 in vivo, we again turned to Drosophila models, in which PINK1 mutants phenocopy parkin mutants 26, 27 . Fbxo7 expression was not able to rescue the PINK1 locomotor deficits, neuron loss, muscle degeneration or mitochondrial disruption (Fig. 5c,d and Supplementary Fig. 6a,b) , suggesting that Fbxo7 and PINK1 may lie in alternative pathways. However, using a PINK1-overexpression phenotypic assay previously used to study PINK1 genetic interactions 7,32 , we found that Fbxo7 did genetically interact with PINK1. Whereas expression of Fbxo7 alone caused no phenotype, coexpression with PINK1 substantially enhanced the PINK1 overexpression 'rough eye' phenotype (Supplementary Fig. 6c) . npg a r t I C l e S These genetic interaction study results are consistent with Fbxo7 having a positive influence on the PINK1-Parkin pathway, but the inability of Fbxo7 to rescue PINK1 mutants suggests that its function may be dependent on PINK1 activity. To test this hypothesis directly, we assessed the ability of Fbxo7 expression to suppress phenotypes in PINK1; parkin double mutants. In contrast to its activity in the parkin mutants, Fbxo7 was unable to rescue climbing and flight defects in the PINK1; parkin double mutant (Fig. 5e,f) . Thus, even though overexpression of human Fbxo7 can suppress parkin mutants, Fbxo7 requires PINK1 activity for its protective function, as is consistent with the data showing Fbxo7 to require PINK1 for its translocation to the mitochondria.
Fbxo7 participates in Mfn ubiquitination
Recent studies have demonstrated that, among a number of outer mitochondrial membrane proteins, Mfns are substrates for Parkinmediated ubiquitination and degradation in response to CCCP treatment [8] [9] [10] 14 . We therefore used ubiquitination of Mfn1 as an additional readout for activation of the Parkin-mediated mitophagy pathway. Treatment with CCCP results in the appearance of ubiquitinated forms of Mfns, as described previously 8, 10, 12, 14 . Immunoblotting of mitochondrial fractions revealed that ubiquitination of Mfn1 was significantly reduced in stable Fbxo7 knockdown SH-SY5Y cells compared to control cells after 1 and 5 h CCCP (P = 0.019, 0.0025; Fig. 6a and Supplementary Fig. 7a ; for level of knockdown, see Supplementary Fig. 7b ). Mfn1 ubiquitination was rescued by overexpression of WT Fbxo7 in the knockdown cells, confirming that this effect is caused by loss of Fbxo7 (Supplementary Fig. 7c) . Moreover, expression of WT Fbxo7 rescued the loss of Mfn1 ubiquitination caused by knockdown of Parkin but not of PINK1 (Supplementary Fig. 7d ). Mfn1 ubiquitination was also reduced in patient fibroblasts homozygous for the R378G mutation (Fig. 6b) , indicating that this mutation interferes with Fbxo7's ability to facilitate Parkin-mediated Mfn1 ubiquitination. Basal Mfn protein levels frequently appeared reduced in Fbxo7-deficient cells compared to controls. This occurred despite a clear reduction in CCCP-induced ubiquitination, which has previously been shown to be Parkindependent [8] [9] [10] 14 , pointing to a possible additional effect of Fbxo7 on Mfn1 levels. Further experiments would be necessary to fully investigate this phenotype.
In Drosophila, loss of parkin or PINK1 leads to an accumulation of unmodified Mfn and mitochondrial hyper-fusion 8 . In agreement with the previous results, expression of Fbxo7 significantly restored the steady state level of Mfn in parkin mutants (P = 0.0273, 0.0107) but was unable to do so in PINK1 mutants (P > 0.9999; Fig. 6c,d) . Similar results were observed with RNA interference knockdown of parkin and PINK1 in cultured Drosophila cells (Supplementary Fig. 7e) . Consistent with these findings, Fbxo7 could prevent mitochondrial hyper-fusion in parkin but not PINK1 knockdown cells (Fig. 6e,f) . Taken together, these results provide further support in vitro and CxVα CxVα Fbxo7 IB: C o n t r o l C o n t r o l p a r k 2 5 , ( 4 ) P I N K 1 B 9 , d a > F b x o 7 ( 4 ) P I N K 1 B 9 , d a > F b x o 7 ( 7 ) p a r k 2 5 , d a > F b x o 7 ( 7 ) Mfn CxVα Mfn levels Mfn levels npg a r t I C l e S in vivo that, like that of Parkin, Fbxo7 expression can regulate Mfn levels but is unable to do so in the absence of PINK1.
Fbxo7 acts in CCCP-induced mitophagy
Parkin recruitment to the mitochondria has been previously shown to result in autophagic clearance of depolarized mitochondria following prolonged treatment with CCCP 1 . Because Fbxo7 appears to participate in Parkin recruitment to the mitochondria, we further investigated its effect on subsequent mitophagy. During induction of autophagy, microtubule-associated protein light chain 3 (LC3) form I is lipidated to its mature form, LC3-II, which localizes to the autophagosome as the autophagosome engulfs the substrate for degradation 33 .
Immunoblotting revealed that in control cells CCCP treatment resulted in a progressive increase in LC3-II at 1 and 5 h in mitochondrial but not cytosolic fractions, whereas in stable Fbxo7-knockdown SH-SY5Y cells formation of LC3-II at the mitochondrion was substantially delayed (Fig. 7a) . Similarly, the ratio of LC3-II to LC3-I was substantially lower in the mitochondrial fraction of patient fibroblasts than in that of controls (Fig. 7b) . LC3-II may be recruited to the mitochondria by the adaptor protein p62, which is also recruited to depolarized mitochondria in a Parkin-dependent manner 4, 34, 35 . Analysis of p62 localization by both immunofluorescence and immunoblotting revealed that this accumulation was substantially reduced in cells transfected with Fbxo7 siRNA compared to controls ( Fig. 7c and Supplementary Fig. 8a ), suggesting that Fbxo7 participates in p62-dependent mitophagy.
A decrease in levels of LC3-II may be explained by a decrease in autophagy or an increase in autophagic turnover 36 . We attempted to monitor autophagic flux by analyzing p62 recruitment to mitochondria after treatment with CCCP and/or bafilomycin. However, we were unable to detect any significant increase in p62 recruitment when Flag-Parkin SH-SY5Y cells were treated with CCCP and bafilomycin compared to those treated with CCCP alone (P = 0.409; data not shown), indicating that this approach may not be appropriate for monitoring mitophagy in this model. To specifically investigate mitochondrial clearance, we therefore employed an immunofluorescence assay, as has been previously reported 1, 4 . Consistent with these reports, we found a substantial proportion of SH-SY5Y cells overexpressing Flag-Parkin to have no remaining mitochondria after 24 h CCCP treatment, whereas untransfected cells retained their mitochondria (Fig. 7d) . This mitochondrial disappearance could be inhibited by bafilomycin (Supplementary Fig. 8b) , which inhibits the lysosomal degradation of proteins, resulting in an accumulation of undegraded LC3-II in the mitochondrial fraction of SH-SY5Y cells after CCCP treatment (Supplementary Fig. 8c ). This inhibition thus confirms that the mitochondrial disappearance observed was due to mitophagy in these cells. The percentage of cells with no remaining mitochondria following CCCP treatment was significantly lower in Flag-Parkinoverexpressing cells transfected with Fbxo7 siRNA than in those transfected with scrambled siRNA (Fig. 7d) . We further confirmed these data in live cells by measuring mitochondrial mass after 24 h CCCP treatment, using DsRed-Mito as an independent mitochondrial marker and calcein to measure cytosolic volume ( Fig. 7e; for representative images, see Supplementary Fig. 8d ).
These data indicating that Fbxo7 can promote mitophagy, coupled with the ability of Fbxo7 to substitute for Parkin in Drosophila, prompted us to test whether Fbxo7 could promote mitophagy in the absence of Parkin in mammalian cells. However, overexpression of Fbxo7 in HeLa cells, which do not express Parkin, failed to induced mitophagy following 24 h CCCP (data not shown). Taken together these results indicate that in mammalian cells Fbxo7 acts to promote mitophagy in a Parkin-dependent manner but is insufficient to induce mitophagy in the absence of Parkin. npg a r t I C l e S Our data show that all three Parkinson's disease-causing mutations in Fbxo7 (T22M, R378G and R498X) interfere with this function in both flies and mammalian cells. The T22M mutation was found to prevent the interaction of Fbxo7 with Parkin and was consequently unable to rescue Parkin translocation to the mitochondria. The R378G mutation, located close to the F-box domain (Fig. 1a) , impaired ubiquitination of Mfn1 but not the ability of Fbxo7 to recruit Parkin to damaged mitochondria, indicating that Fbxo7's role in the PINK1-Parkin mitophagy pathway is not limited to the recruitment of Parkin but that it also participates in substrate ubiquitination. The R378G mutation was previously shown to impair Fbxo7's interaction with Skp1 and, through it, the SCF complex 37 , raising the possibility that Fbxo7 may facilitate Parkin-dependent ubiquitination in an SCF-dependent manner. Finally, the R498X truncation was unable to recruit Parkin to the mitochondria, indicating an involvement of the C-terminal proline-rich region of the protein in this step. This domain is involved in forming protein-protein interactions, but our data show that it does not participate in the interaction with Parkin, suggesting that another protein or proteins interacting with this domain of Fbxo7 is important for recruitment of Parkin to the mitochondria.
The precise mechanism by which Parkin, a cytosolic protein, translocates to depolarized mitochondria remains poorly defined, despite a clear dependence on the mitochondrial localization of PINK1 (refs. 2-4). We identified an MTS in the N terminus of Fbxo7 and found that this was essential for its recruitment of Parkin to the mitochondria, raising the possibility that Fbxo7 may participate in the physical translocation of Parkin to mitochondria. In support of this hypothesis, when both proteins were overexpressed in cells the interaction was found to occur in both cytosolic and mitochondrial fractions.
It is worth noting that Drosophila parkin mutants completely lack Parkin protein, ruling out the possibility that the observed rescue by human Fbxo7 could arise from an increased recruitment of residual parkin to the mitochondria and suggesting that Fbxo7 may cooperate with another E3 ubiquitin ligase that remains to be identified. The finding that none of the three pathogenic mutants were able to rescue the loss of parkin phenotype in vivo further supports the idea that this activity to maintain mitochondria homeostasis is defective in PARK15 patients.
We found Fbxo7 to function downstream of PINK1 in mammalian cells because Fbxo7 relocation was PINK1 dependent, but found that Fbxo7 overexpression failed to rescue the effects of PINK1 silencing in mammalian cells or in Drosophila. This failure to rescue loss of PINK1 may be because Fbxo7's role in the pathway absolutely requires PINK1 activity; for example, if phosphorylation of either Fbxo7 itself or its substrate(s) by PINK1 is necessary for Fbxo7 function at the mitochondria. PINK1 has been reported to phosphorylate Parkin but not Fbxo7 (ref. 38) , suggesting that the latter hypothesis may be more likely.
In conclusion, this study demonstrates that Fbxo7 participates in Parkin recruitment to damaged mitochondria, Mfn1 ubiquitination and mitophagy. This finding places further emphasis on the importance of mitochondrial turnover in neuroprotection and as a contributing factor in Parkinson's disease.
METHODS
Methods and any associated references are available in the online version of the paper. 
